Scientific papers and presentations

Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies

Newest first
Oldest first

Posters & Papers
Presentations

26/06/2019

VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION Oslo, June 26, 2019

20/05/2019

BRINGING INDIVIDUALISED NEOANTIGEN-BASED CANCER VACCINES INTO THE CLINIC; CHALLENGES, LEARNINGS & VICTORIES | Amsterdam, April 2019

03/04/2019

VACCIBODY DNA VACCINE PLATFORM VB10.NEO INDUCES STRONG NEO-ANTIGEN SPECIFIC CD8+ T CELL RESPONSES CRITICAL TO CURE ESTABLISHED TUMORS IN PRE-CLINICAL MODELS | Atlanta, April 2019

03/04/2019

SAFETY, EFFICACY AND IMMUNOGENICITY OF VB10.16, A THERAPEUTIC DNA VACCINE TARGETING HUMAN PAPILLOMAVIRUS (HPV) 16 E6 AND E7 PROTEINS FOR HIGH GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN 2/3): 6-MONTH DATA FROM AN EXPLORATORY OPEN-LABEL PHASE I/2A TRIAL | Atlanta, April 2019

03/04/2019

AN OPEN-LABEL, PHASE I/IIA STUDY OF VB10.NEO (DIRECT-01) IN COMBINATION WITH CHECKPOINT BLOCKADE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS INCLUDING MELANOMA, NSCLC, RENAL CELL CARCINOMA, UROTHELIAL CANCER OR SSCHN | Atlanta, April 2019

Pages: 123456789